PL1817013T3 - Dojelitowa powlekana peletka zawierająca Ixabepilone - Google Patents

Dojelitowa powlekana peletka zawierająca Ixabepilone

Info

Publication number
PL1817013T3
PL1817013T3 PL05824194T PL05824194T PL1817013T3 PL 1817013 T3 PL1817013 T3 PL 1817013T3 PL 05824194 T PL05824194 T PL 05824194T PL 05824194 T PL05824194 T PL 05824194T PL 1817013 T3 PL1817013 T3 PL 1817013T3
Authority
PL
Poland
Prior art keywords
ixabepilone
enteric coated
coated bead
bead
enteric
Prior art date
Application number
PL05824194T
Other languages
English (en)
Inventor
Ismat Ullah
Gary James Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PL1817013T3 publication Critical patent/PL1817013T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL05824194T 2004-11-18 2005-11-17 Dojelitowa powlekana peletka zawierająca Ixabepilone PL1817013T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62897004P 2004-11-18 2004-11-18
EP05824194A EP1817013B1 (en) 2004-11-18 2005-11-17 Enteric coated bead comprising ixabepilone
PCT/US2005/041736 WO2006055740A1 (en) 2004-11-18 2005-11-17 Enteric coated bead comprising ixabepilone, and preparation thereof

Publications (1)

Publication Number Publication Date
PL1817013T3 true PL1817013T3 (pl) 2009-01-30

Family

ID=35976527

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05824194T PL1817013T3 (pl) 2004-11-18 2005-11-17 Dojelitowa powlekana peletka zawierająca Ixabepilone

Country Status (26)

Country Link
US (1) US20060153917A1 (pl)
EP (2) EP1958625A1 (pl)
JP (1) JP2008520696A (pl)
KR (1) KR20070084325A (pl)
CN (1) CN101083978A (pl)
AR (1) AR052142A1 (pl)
AT (1) ATE397442T1 (pl)
AU (1) AU2005306464A1 (pl)
BR (1) BRPI0518286A2 (pl)
CA (1) CA2588400A1 (pl)
DE (1) DE602005007376D1 (pl)
DK (1) DK1817013T3 (pl)
ES (1) ES2306278T3 (pl)
HK (1) HK1106713A1 (pl)
HR (1) HRP20080349T3 (pl)
IL (1) IL183116A0 (pl)
MX (1) MX2007005763A (pl)
NO (1) NO20072388L (pl)
PE (1) PE20061058A1 (pl)
PL (1) PL1817013T3 (pl)
PT (1) PT1817013E (pl)
RU (1) RU2349319C1 (pl)
SI (1) SI1817013T1 (pl)
TW (1) TW200631609A (pl)
WO (1) WO2006055740A1 (pl)
ZA (1) ZA200703955B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101091725A (zh) 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
EP3117709B1 (en) 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
US9156189B2 (en) 2010-10-01 2015-10-13 The Johns Hopkins University Systems and methods for high-throughput microfluidic bead production
EP2672981B1 (en) 2011-02-11 2018-03-28 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
EP2988824B1 (en) 2013-04-23 2018-11-07 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
ES2178093T5 (es) * 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilon y su preparacion.
JP4090529B2 (ja) * 1996-01-24 2008-05-28 フロイント産業株式会社 乳糖の球形粒及びその製造方法
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE69732780T2 (de) * 1996-10-02 2006-04-06 Novartis Ag Pyrimiderivate und verfahren zu ihrer herstellung
PT941227E (pt) * 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
CN1128803C (zh) * 1997-02-25 2003-11-26 生物技术研究有限公司(Gbf) 环氧噻嗪酮b－n－氧化物及其制备方法
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
AU765957B2 (en) * 1998-10-01 2003-10-02 Powderject Research Limited Spray coated microparticles for use in needleless syringes
EE200100431A (et) * 1999-02-18 2002-12-16 Schering Aktiengesellschaft 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
US6262094B1 (en) * 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
PL355844A1 (pl) * 2000-08-09 2004-05-31 Panacea Biotec Limited Nowe farmaceutyczne kompozycje leków przeciw gruźlicy oraz sposoby ich wytwarzania
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1319011B1 (de) * 2000-09-22 2012-12-05 Helmholtz-Zentrum für Infektionsforschung GmbH Triazolo-epothilone
EP1191127B1 (de) 2000-09-26 2004-10-13 Enthone-OMI (Deutschland) GmbH Verfahren zur selektiven Metallisierung dielektrischer Materialien
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
HU229349B1 (en) * 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
JP2004521122A (ja) * 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
CA2438598A1 (en) * 2001-02-20 2002-08-29 Francis Y. F. Lee Epothilone derivatives for the treatment of refractory tumors
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
CZ305799B6 (cs) * 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
EP1392664A4 (en) * 2001-06-01 2005-01-26 Bristol Myers Squibb Co EPOTHILONE DERIVATIVES
JP4645789B2 (ja) * 2001-06-18 2011-03-09 Ｊｓｒ株式会社 ネガ型感放射線性樹脂組成物
DE60330651D1 (en) * 2002-03-12 2010-02-04 Bristol Myers Squibb Co C3-cyanoepothilonderivate
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003256157A1 (en) * 2002-08-05 2004-02-23 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
WO2004032866A2 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof

Also Published As

Publication number Publication date
PT1817013E (pt) 2008-08-07
TW200631609A (en) 2006-09-16
HK1106713A1 (en) 2008-03-20
DK1817013T3 (da) 2008-10-13
SI1817013T1 (sl) 2008-12-31
EP1817013B1 (en) 2008-06-04
JP2008520696A (ja) 2008-06-19
DE602005007376D1 (de) 2008-07-17
WO2006055740A1 (en) 2006-05-26
EP1958625A1 (en) 2008-08-20
US20060153917A1 (en) 2006-07-13
HRP20080349T3 (en) 2009-01-31
RU2349319C1 (ru) 2009-03-20
AU2005306464A1 (en) 2006-05-26
KR20070084325A (ko) 2007-08-24
EP1817013A1 (en) 2007-08-15
MX2007005763A (es) 2007-07-20
PE20061058A1 (es) 2006-10-13
CA2588400A1 (en) 2006-05-26
AR052142A1 (es) 2007-03-07
ES2306278T3 (es) 2008-11-01
IL183116A0 (en) 2007-09-20
NO20072388L (no) 2007-06-14
CN101083978A (zh) 2007-12-05
ZA200703955B (en) 2008-08-27
BRPI0518286A2 (pt) 2008-11-11
ATE397442T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
TWI307630B (en) Immunoglobulins
IL181575A0 (en) Anti-ox40l antibodies
IL228033A0 (en) Antibodies
GB0420164D0 (en) A scheduler
EP1798006A4 (en) ROBOT
HK1106713A1 (en) Enteric coated bead comprising ixabepilone
EP1754545A4 (en) PAINT PROCESS
GB0420466D0 (en) Anti-glucan antibodies
EP1754544A4 (en) PAINT PROCESS
EP1727729A4 (en) BICYCLE SUSPENSION ARRANGEMENT
ZA200701952B (en) Anti-OX40L antibodies
EP1737655A4 (en) REINFORCING RING APPLICATOR
GB0407197D0 (en) Immunoglobulins
GB2411693B (en) Pivotable suspension element
GB0400382D0 (en) Novel processes
GB0400329D0 (en) Novel processes
HU0400218V0 (en) Coated curd-dessert
GB0410739D0 (en) Flexible bead applicator
GB0402298D0 (en) Flex guider
HK1062775A2 (en) 9 beads
GB0400405D0 (en) Novel processes
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies
GB0420391D0 (en) Coatings
AU300589S (en) Tyre